Evidence map›Paper›PMID 33692499›Full record

ReviewNature reviews. Urology2021

Epidemiology and genomics of prostate cancer in Asian men.

Yao Zhu, Miao Mo, Yu Wei, Junlong Wu, Jian Pan, Stephen J Freedland, Ying Zheng, Dingwei Ye

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05577689 (Combining Multi-omics Analysis and Organoid Models to Search for Novel Therapy Target in Metastatic Prostate Cancer), which is not on this map. Cited by 175 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
175citing papers in PubMed, 10 pooled it
29.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05577689 recruitingnot on this mapstarted 2023, after this paper: background citation

Combining Multi-omics Analysis and Organoid Models to Search for Novel Therapy Target in Metastatic Prostate Cancer

TypeobservationalSponsorFudan UniversityRan2023 to 2028Enrolled100ConditionsProstate NeoplasmsArmsTissue
3 · Its place in the literature

Who cites it

175 citing papers in PubMed, 10 syntheses or guidelines pooled it, 288 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

115 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Yao ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. yaozhu09@fudan.edu.cn.
Miao MoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yu WeiDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Junlong WuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0002-4125-7975
Jian PanDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Stephen J FreedlandDepartment of Surgery, Division of Urology and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ying ZhengDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. dwyeli@163.com.
Shanghai Medical College of Fudan University · CNCedars-Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is a global health problem, but incidence varies considerably across different continents. Asia is traditionally considered a low-incidence area, but the incidence and mortality of prostate cancer have rapidly increased across the continent. Substantial differences in epidemiological features have been observed among different Asian regions, and incidence, as well as mortality-to-incidence ratio, is associated with the human development index. Prostate cancer mortality decreased in Japan and Israel from 2007 to 2016, but mortality has increased in Thailand, Kyrgyzstan and Uzbekistan over the same period. Genomic analyses have shown a low prevalence of ERG oncoprotein in the East Asian population, alongside a low rate of PTEN loss, high CHD1 enrichments and high FOXA1 alterations. Contributions from single-nucleotide polymorphisms to prostate cancer risk vary with ethnicity, but germline mutation rates of DNA damage repair genes in metastatic prostate cancer are comparable in Chinese and white patients from the USA and UK. Pharmacogenomic features of testosterone metabolism might contribute to disparities seen in the response to androgen deprivation between East Asian men and white American and European men. Overall, considerable diversity in epidemiology and genomics of prostate cancer across Asia defines disease characteristics in these populations, but studies in this area are under-represented in the literature. Taking into account this intracontinental and intercontinental heterogeneity, translational studies are required in order to develop ethnicity-specific treatment strategies.

Indexed as

GenomicsAsian PeopleHumansIncidenceMaleProstatic Neoplasms

Identifiers

PMID33692499
OpenAlexW3134889720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.